Diabetes Research and Clinical Practice
Volume 75, Issue 3 , Pages 267-277 , March 2007

Role of angiotensin II type-1 and type-2 receptors on vascular smooth muscle cell growth and glucose metabolism in diabetic rats

Received 24 February 2006 ,Revised 7 June 2006 ,Accepted 26 June 2006.

References 

  1. National High Blood Pressure Education Program Working Group . National High Blood Pressure Education Program Working Group Report on hypertension in diabetes. Hypertension. 1994;23:145–158
  2. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure. JAMA. 1998;280:140–146
  3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart diseases and in non-diabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998;339:229–234
  4. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hender T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611–618
  5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001;345:861–869
  6. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardio-vascular morbidity and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004–1010
  7. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031
  8. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, et al. Risk of new-onset diabetes in the Losartan intervention for endpoint reduction in hypertension study. J. Hypertens. 2002;20:1879–1886
  9. Dzau VJ. Cell biology and genetics of angiotensin in cardiovascular disease. J. Hypertens. 1994;12(Suppl.):S3–S10
  10. Natajaran R, Scott S, Bai W, Yerneni KKV, Nadler J. Angiotensin II signaling in vascular smooth muscle cells under high glucose conditions. Hypertension. 1999;33:378–384
  11. Ni W, Kitamoto S, Ishibashi M, Usui M, Inoue S, Hiasa K, et al. Monocyte chemo-attractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler. Thromb. Vasc. Biol. 2004;24:534–539
  12. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels: a potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J. Clin. Invest. 1997;100:2158–2169
  13. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and biochemical basis of diabetic complications. N. Engl. J. Med. 1998;318:1315–1321
  14. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension. 1999;33:1130–1134
  15. Igarashi M, Hirata A, Yamaguchi H, Tsuchiya H, Ohnuma H, Tominaga M, et al. Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats. Hypertension. 2001;38:1255–1259
  16. Ran J, Hirano T, Adachi M. Angiotensin II type 1 receptor blocker ameliorates over-production and accumulation of tryglyceride in the liver of Zucker fatty rats. Am. J. Physiol. Endocrinol. Metab. 1994;287:E227–E232
  17. Hsieh PS, Tai YH, Loh CH, Shih KC, Cheng WT, Chu CH. Functional interaction of AT1 and AT2 receptors in fructose-induced insulin resistance and hypertension. Metabolism. 2005;54:157–164
  18. Zhang X, Lassila M, Cooper ME, Cao Z. Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension. 2004;43:276–281
  19. Ikeda H, Shino A, Matsuo T, Iwatsuka H, Suzuoki Z. A new genetically obese-hyperglycemic rat (Wistar fatty). Diabetes. 1981;30:1045–1050
  20. Igarashi M, Takeda Y, Ishibashi N, Takahashi K, Mori S, Tominaga M, et al. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization. Horm. Metab. Res. 1997;29:444–449
  21. Igarashi M, Yamaguchi H, Hirata A, Tsuchiya H, Ohnuma H, Tominaga M, et al. Mechanism of inhibitory effect of cerivastatin on rat vascular smooth muscle cell growth. J. Cardiovasc. Pharmacol. 2002;40:277–287
  22. Hirata A, Igarashi M, Yamaguchi H, Suwabe A, Daimon M, Kato T, et al. Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK–ERK pathway coupling with Pyk2. Br. J. Pharmacol. 2000;131:1521–1530
  23. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1606
  24. Kim YK, Lee MS, Son SM, Kim IJ, Lee WS, Rhim BY, et al. Vascular NADH oxidase is involved in ompaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes. 2002;51:522–527
  25. Schofield I, Malik R, Izzard A, Austin C, Heagerty A. Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation. 2002;106:3037–3043
  26. Pandolfi A, Grilli A, Cilli C, Patruno A, Giaccari A, Silvestre S, et al. Phenotype modulation in cultures of vascular smooth muscle cells from diabetic rats: association with increased nitric oxide synthase expression and superoxide anion generation. J. Cell. Physiol. 2003;196:378–385
  27. Taniyama Y, Hitomi H, Shah A, Alexander RW, Griendling KK. Mechanism of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. Arterioscler. Thromb. Vasc. Biol. 2005;25:1142–1147
  28. Wehbi GJ, Zimpelmann J, Carey RM, Levine DZ, Burns KD. Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am. J. Physiol. Renal Physiol. 2001;280:F254–F265
  29. Arun KH, Kaul CL, Poduri R. Temporal augments angiotensin II-induced AT2 receptor-mediated relaxation in diabetic rat thoracic aorta. J. Hypertens. 2004;22:2143–2152
  30. Garnovskaya MN, Mukhin YV, Vlasova TM, Grewal JS, Ullian ME, Tholanikunnel BG, et al. Mitogen-induced rapid phosphorylation of serine 795 of the retinoblastoma gene product in vascular smooth muscle cells involves ERK activation. J. Biol. Chem. 1994;279:24899–24905
  31. Vanhoutte P, Barnier JV, Guibert B, Pages C, Besson MJ, Hipskind RA, et al. Glutamate induces phosphorylation of Elk-1 and CREB, along with c-fos activation, via an extracellular signal-regulated kinase-dependent pathway in brain slices. Mol. Cell. Biol. 1999;19:136–146
  32. Wang Q, Somwar R, Bilan PJ, Liu Z, Jin J, Woodgett JR, et al. Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol. Cell. Biol. 1999;19:4008–4018
  33. Kim YB, Nikoulina SE, Ciaraldi TP, Henry RP, Kahn BB. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J. Clin. Invest. 1999;104:733–741
  34. Standley PR, Rose KA. Insulin and insulin-like growth factor-1 modulation of glucose transport in arterial smooth muscle cells. Implication of GLUT-4 in the vasculature. Am. J. Hypertens. 1994;7:357–362
  35. Nickenig G, Roling J, Strehlow K, Schnabel P, Bohm M. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation. 1998;98:2453–2460
  36. Shiuchi T, Iwai M, Li HS, Wu LL, Min LJ, Li JM, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension. 2004;43:1003–1010
  37. Riu L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, et al. Insulin/IGF-1 and TNF-α stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J. Clin. Invest. 2001;107:181–189
  38. Zick Y. Role of Ser/Thr kinases in the uncoupling of insulin signaling. Int. J. Obes. Relat. Metab. Disord. 2003;27(Suppl. 3):S56–S60

PII: S0168-8227(06)00311-1

doi: 10.1016/j.diabres.2006.06.032

Diabetes Research and Clinical Practice
Volume 75, Issue 3 , Pages 267-277 , March 2007

Article Tools

* Image Usage & Resolution